Trump Signs Executive Order to Expedite Psychedelic Research for PTSD Treatment
President Donald Trump signed an executive order to accelerate research and access to psychedelics, particularly ibogaine, for treating PTSD and other mental health conditions. The order directs the FDA to issue new guidance for researchers and allocates $50 million for federal research into ibogaine, which is currently classified as a Schedule I controlled substance. The move aims to provide alternative treatments for patients with severe conditions.
Topics: FDA government_regulation mental_health psychedelics Trump_administration